D.E. Shaw & Co
UPB

D.E. Shaw & Co’s Upstream Bio Inc UPB Stock Holding History

D.E. Shaw & Co’s Portfolio UPB Stock Details UPB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.38M Buy
820,480
+793,389
+2,929% +$14.3M ﹤0.01% 1869
2025
Q4 		$736K Buy
+27,091
New +$674K ﹤0.01% 3727

Other funds holding UPB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co's UPB Position: Q1 2026 in Review

D.E. Shaw & Co increased its Upstream Bio Inc (UPB) stake by 2,929% in Q1 2026, buying an estimated $14.3M and bringing the position to 820,480 shares worth $7.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1869.

D.E. Shaw & Co first reported a position in UPB in Q4 2025 and has held it in 2 quarters since. 140 funds tracked by Wall St. Rank hold UPB as of Q1 2026.

  • D.E. Shaw & Co held 820,480 shares of Upstream Bio Inc worth $7.38M as of Q1 2026.
  • D.E. Shaw & Co bought 793,389 Upstream Bio Inc shares in Q1 2026, an estimated $14.3M.
  • Upstream Bio Inc made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1869 holding.
  • D.E. Shaw & Co first reported a position in Upstream Bio Inc in Q4 2025 and has held it in 2 quarters since.
  • 140 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.